Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inovio Pharmaceuticals (INO), Conatus Pharmaceuticals (CNAT) and Aptose Biosciences (APTO).
Inovio Pharmaceuticals (INO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $13. The company’s shares closed yesterday at $3.72.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.4% and a 35.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.40, a 179.6% upside from current levels. In a report issued on March 12, Piper Jaffray also maintained a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
Conatus Pharmaceuticals (CNAT)
Conatus Pharmaceuticals received a Hold rating and a $1.50 price target from H.C. Wainwright analyst Ed Arce today. The company’s shares closed yesterday at $2.91.
Arce said:
“916-3963, Probability of success (POS) Prob-adj Value Full value S/O as of POLT, U.S. 10% $0.03 $0.34 Shares outstanding 33,165 Emricasan for cirrhosis, U.S.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 10.3% and a 44.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Conatus Pharmaceuticals with a $9 average price target, a 209.3% upside from current levels. In a report released today, SunTrust Robinson also downgraded the stock to Hold.
Aptose Biosciences (APTO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences today and set a price target of $8.50. The company’s shares closed yesterday at $2.43.
Pantginis commented:
“Valuation and impediments to achieving price target. We reiterate our Buy and $8.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from both the CG-806 opportunity in AML and APTO-253 opportunity in AML and MDS. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -12.5% and a 33.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.25 average price target, implying a 198.4% upside from current levels. In a report issued on March 13, Oppenheimer also assigned a Buy rating to the stock with a $6 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
